Literature DB >> 20039802

Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.

Beverlie Baquir1, Lin Lin, Ashraf S Ibrahim, Yue Fu, Valentina Avanesian, Ang Tu, John Edwards, Brad Spellberg.   

Abstract

We determined reactivity of human blood to a vaccine based on the recombinant N-terminus of candidal Als3p (rAls3p-N) in preparation for future clinical trials. Healthy donor plasma had high immunoglobulin G titers (median, 1:51,200) and lower immunoglobulin A (median, 1:3,200) and immunoglobulin E (median, 1:128) titers to rAls3p-N by enzyme-linked immunosorbent assay. rAls3p-N stimulated interferon gamma (IFN-gamma) and interleukin (IL)-17, but not IL-4, from donor lymphocytes by enzyme-linked immunosorbent spot assay and IL-12 p70, IFN-gamma, IL-17, and IL-10 by cytometric bead array. Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20039802      PMCID: PMC2812804          DOI: 10.1086/649901

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

2.  Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Lin Lin; Valentina Avanesian; Yue Fu; Peter Lipke; Henry Otoo; Tiffany Ho; John E Edwards
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

3.  Responses of children immunized with capsular polysaccharide of Hemophilus influenzae type b, by David H. Smith, MD, et al, Pediatrics, 1973;52:637-644; and Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland, by Heikki Peltola, MD et al, Pediatrics, 1977;60:730-737.

Authors:  C G Peter
Journal:  Pediatrics       Date:  1998-07       Impact factor: 7.124

4.  Epidemiological studies of Streptococcus pneumoniae in infants: antibody to types 3, 6, 14, and 23 in the first two years of life.

Authors:  B M Gray; H C Dillon
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

5.  Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.

Authors:  D M Musher; J E Groover; J M Rowland; D A Watson; J B Struewing; R E Baughn; M A Mufson
Journal:  Clin Infect Dis       Date:  1993-07       Impact factor: 9.079

6.  Candida albicans ALS3 and insights into the nature of the ALS gene family.

Authors:  L L Hoyer; T L Payne; M Bell; A M Myers; S Scherer
Journal:  Curr Genet       Date:  1998-06       Impact factor: 3.886

Review 7.  Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

Authors:  Joshua Perlroth; Bryan Choi; Brad Spellberg
Journal:  Med Mycol       Date:  2007-06       Impact factor: 4.076

8.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Michael R Yeaman; Lin Lin; Yue Fu; Valentina Avanesian; Arnold S Bayer; Scott G Filler; Peter Lipke; Henry Otoo; John E Edwards
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

10.  Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.

Authors:  Lin Lin; Ashraf S Ibrahim; Valentina Avanesian; John E Edwards; Yue Fu; Beverlie Baquir; Rebecca Taub; Brad Spellberg
Journal:  Clin Vaccine Immunol       Date:  2008-01-09
View more
  9 in total

1.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Authors:  Brenna C Simons; Philip R Spradling; Dana J T Bruden; Carolyn Zanis; Samantha Case; Tammy L Choromanski; Minjun Apodaca; Hazel D Brogdon; Gaelen Dwyer; Mary Snowball; Susan Negus; Michael G Bruce; Chihiro Morishima; Cindy Knall; Brian J McMahon
Journal:  J Infect Dis       Date:  2016-04-07       Impact factor: 5.226

Review 2.  Universal fungal vaccines: could there be light at the end of the tunnel?

Authors:  Mawieh Hamad
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 3.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

4.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

5.  Universal vaccines: shifting to one for many.

Authors:  Antonio Cassone; Rino Rappuoli
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

Review 6.  Recent progress in vaccines against fungal diseases.

Authors:  Antonio Cassone; Arturo Casadevall
Journal:  Curr Opin Microbiol       Date:  2012-05-06       Impact factor: 7.934

7.  New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges.

Authors:  Anna Vecchiarelli; Eva Pericolini; Elena Gabrielli; Donatella Pietrella
Journal:  Front Microbiol       Date:  2012-08-13       Impact factor: 5.640

Review 8.  Vaccines against Coccidioides.

Authors:  Hee Jung Yoon; Karl V Clemons
Journal:  Korean J Intern Med       Date:  2013-07-01       Impact factor: 2.884

Review 9.  Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.

Authors:  Michael R Yeaman; Scott G Filler; Clint S Schmidt; Ashraf S Ibrahim; John E Edwards; John P Hennessey
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.